logo
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Biohaven Ltd. (BHVN) Investors To Inquire About Securities Fraud Class Action

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Biohaven Ltd. (BHVN) Investors To Inquire About Securities Fraud Class Action

Business Wire5 days ago
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Biohaven Ltd. ('Biohaven' or the 'Company') (NYSE: BHVN) securities between March 24, 2023 and May 14, 2025, inclusive (the 'Class Period'). Biohaven investors have until September 12, 2025 to file a lead plaintiff motion.
IF YOU SUFFERED A LOSS ON YOUR BIOHAVEN LTD. (BHVN), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS
What Happened?
On July 17, 2023, Biohaven disclosed that the FDA had rejected the New Drug Application ('NDA') for its spinocerebellar ataxia ('SCA') treatment, troriluzole, having refused to even review the application after the Phase 3 SCA Trial had failed to meet its primary endpoint. On this news, Biohaven's stock price fell $5.38, or 22.6%, to close at $18.42 per share on July 27, 2023, thereby injuring investors.
Then, on March 3, 2025, Biohaven released its fourth quarter and full year 2024 financial results, disclosing that recent data from a late-stage study of its BHV-7000 treatment for bipolar mania 'did not statistically separate from the comparator on the Young Mania Rating Scale primary outcome measure[.]' On this news, Biohaven's stock price fell $5.12, or 13.8%, to close at $32.06 per share on March 3, 2025.
Then, on April 25, 2025, news reports emerged that, according to the European Medicines Agency ('EMA'), Biohaven had withdrawn its Marketing Authorization Application ('MAA') for troriluzole in late March 2025. On this news, Biohaven's stock price fell $3.56, or 15.2%, to close at $19.84 per share on April 25, 2025.
Then, on May 14, 2025, Biohaven announced that 'the Division of Neurology 1 within FDA's Office of Neuroscience informed the Company that they are extending the [Prescription Drug User Fee Act ('PDUFA')] date for the troriluzole [NDA] for the treatment of [SCA] by three months to provide time for a full review of Biohaven's recent submissions related to information requests from the FDA,' and that '[t]he Division also informed Biohaven that it is currently planning to hold an advisory committee meeting to discuss the application, but no date has been scheduled.' On this news, Biohaven's stock price fell $3.84, or 19.5%, to close at $15.82 per share on May 15, 2025, thereby injuring investors further.
What Is The Lawsuit About?
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) troriluzole's regulatory prospects as a treatment for SCA, and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to have a significant negative impact on Biohaven's business and financial condition; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
If you purchased or otherwise acquired Biohaven securities during the Class Period, you may move the Court no later than September 12, 2025 to request appointment as lead plaintiff in this putative class action lawsuit.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150,
Toll-Free: 888-773-9224
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Steady Dividends from Industrial Strength: Pentair (PNR) in Focus
Steady Dividends from Industrial Strength: Pentair (PNR) in Focus

Yahoo

time3 minutes ago

  • Yahoo

Steady Dividends from Industrial Strength: Pentair (PNR) in Focus

Pentair plc (NYSE:PNR) is included among the Top 10 Safest Dividend Stocks in the UK. A factory worker with protective goggles and a hardhat inspecting a water filtration system. Pentair plc (NYSE:PNR) is an American company focused on water treatment solutions. While its headquarters are in the United States, the company is legally registered in Ireland and has its tax residence in the United Kingdom. Piper Sandler recently identified Pentair plc (NYSE:PNR) as a leading contender in the artificial intelligence surge. The firm started covering the software company with an Overweight rating and set a price target of $175, indicating a potential upside of around 13% from Palantir's closing price on Thursday. Pentair plc (NYSE:PNR) recently reported its earnings for the second quarter of 2025 and demonstrated a strong cash position. The company's operating cash flow was $607 million, and its free cash flow was $596 million. It also paid $82.4 million to shareholders through dividends. In addition, PNR has been rewarding its shareholders with growing dividends for the past 49 years. Currently, it pays a quarterly dividend of $0.25 per share and has a dividend yield of 0.97%, as of July 25. While we acknowledge the potential of PNR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Sign in to access your portfolio

British American Tobacco (BTI): A High-Yield Dividend Stock with Defensive Strength
British American Tobacco (BTI): A High-Yield Dividend Stock with Defensive Strength

Yahoo

time3 minutes ago

  • Yahoo

British American Tobacco (BTI): A High-Yield Dividend Stock with Defensive Strength

British American Tobacco p.l.c. (NYSE:BTI) is included among the Top 10 Safest Dividend Stocks in the UK. A close-up of an array of tobacco products, emphasizing the selection and consumer choice. British American Tobacco p.l.c. (NYSE:BTI) is among the best FTSE dividend stocks. Similar to its industry peers, the company is heavily focused on shifting towards next-generation products. What sets BAT apart is its global reach, offering investors exposure to the worldwide tobacco market rather than being limited to just the US or international markets alone. Its product lineup spans traditional cigarettes, vaporizers, heated tobacco, and smokeless options like chewing tobacco. For those looking to invest in the broader tobacco sector, BAT offers a straightforward, all-in-one entry point through a single stock. In July, Jefferies began covering British American Tobacco p.l.c. (NYSE:BTI) with a Buy rating, selecting it as their top pick within the tobacco industry. The firm pointed to the company's growing profitability in its traditional combustibles segment as a key driver supporting its progress in expanding into smoke-free products. Analysts also highlighted British American Tobacco p.l.c. (NYSE:BTI)'s strong financial position and solid cash returns, while suggesting that there is still potential for margin improvement. From a valuation perspective, the stock was considered appealing, trading at a 35% discount compared to other tobacco firms — a gap Jefferies expects could close over time. British American Tobacco p.l.c. (NYSE:BTI) has raised its payouts every year since 2018. The company offers a quarterly dividend of $0.7391 per share and has a dividend yield of 5.8%, as recorded on July 25. While we acknowledge the potential of BTI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.

Is NatWest (NWG) Quietly Becoming One of the UK's Most Reliable Dividend Payers?
Is NatWest (NWG) Quietly Becoming One of the UK's Most Reliable Dividend Payers?

Yahoo

time3 minutes ago

  • Yahoo

Is NatWest (NWG) Quietly Becoming One of the UK's Most Reliable Dividend Payers?

NatWest Group plc (NYSE:NWG) is included among the Top 10 Safest Dividend Stocks in the UK. A person using a laptop to access a bank's online banking system. NatWest Group plc (NYSE:NWG) is an Edinburgh-based company that offers mortgages, loans, credit cards, and related services. The company recently announced its results for the first half of the year, highlighting a £4.2 billion increase in net loans to customers, bringing the total to £336.2 billion. This figure includes £2.2 billion in personal loans and credit card balances acquired from Sainsbury's Bank as of June 30, 2025. Within Retail Banking, NatWest Group plc (NYSE:NWG)'s mortgage balances grew by £4.1 billion, while Commercial & Institutional balances rose by £2.0 billion, mainly due to increased lending activity in the Commercial Mid-market segment, particularly to housebuilders and housing associations, as well as within the Corporate & Institutions division. NatWest Group plc (NYSE:NWG) reported an operating cash flow of £2.5 billion. The company also returned £1.4 billion to shareholders through dividends during this period. Its semi-annual dividend comes in at $0.1543 per share for a dividend yield of 3.92%, as of July 25. While we acknowledge the potential of NWG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store